Canada
Breast Cancer Therapeutics Market is anticipated to witness impressive growth during
the forecast period. Also, growing availability of highly effective medications
is expected to drive the growth of Canada Breast Cancer Therapeutics Market
during the forecast period. For instance, in 2020, about 27,400 women were diagnosed
with breast cancer in Canada.
Increasing
Breast Cancer Incidences
The
increasing incidence of breast cancer in Canada has a significant impact on the
growth of the Canada Breast Cancer Therapeutics Market. The growing number of
breast cancer cases translates into a larger patient population requiring
treatment. This increased patient base creates a higher demand for breast
cancer therapeutics, including surgery, radiation therapy, chemotherapy,
targeted therapies, and hormonal therapies. The rising incidence of breast
cancer contributes to the expansion of the market size and generates increased
revenue opportunities for pharmaceutical companies, healthcare providers, and
other stakeholders involved in breast cancer therapeutics. The market growth is
driven by the need to cater to the growing patient population and provide
effective treatment options. The increasing breast cancer incidence motivates
greater investments in research and development (R&D) efforts focused on
understanding the disease, discovering new treatment modalities, and improving
existing therapies. Pharmaceutical companies, academic institutions, and
government organizations allocate resources to develop innovative therapeutics
to meet the growing demand for effective treatments. The rise in breast cancer
incidence has led to a deeper understanding of the molecular and genetic basis
of the disease. This knowledge has facilitated the development of targeted
therapies that specifically act on cancer cells, reducing off-target effects
and improving treatment outcomes. The demand for targeted therapies increases
as the incidence of breast cancer rises, driving research and innovation in
this area. The increasing incidence of breast cancer necessitates the conduct
of more clinical trials to evaluate the safety and efficacy of novel
therapeutics. These trials generate valuable data that contribute to the
evidence base supporting the use of specific treatment options. The
availability of robust clinical trial data is crucial in gaining regulatory
approvals and facilitating the adoption of new therapeutics in clinical
practice. According to Canadian Cancer Society, 28,600 Canadian women were diagnosed
with breast cancer. This represents 25% of all new cancer cases in women in
2022.
Growing
Technological Advancements
Technological
advancements have a profound impact on the growth of the Canada Breast Cancer
Therapeutics Market. Technological advancements in breast imaging techniques,
such as digital mammography, magnetic resonance imaging (MRI), and molecular
breast imaging, have improved the accuracy and early detection of breast
cancer. These advanced imaging modalities enable healthcare professionals to
detect tumors at smaller sizes and at earlier stages, leading to more effective
treatment outcomes. Consequently, the demand for therapeutics targeting
early-stage breast cancer increases, driving market growth. Technological
advancements have facilitated the growth of precision medicine approaches in
breast cancer treatment. Genetic profiling and molecular testing techniques,
such as next-generation sequencing, allow healthcare providers to identify
specific genetic alterations and biomarkers associated with breast cancer. This
information enables the development of personalized treatment plans tailored to
individual patients, maximizing treatment efficacy while minimizing side
effects. The adoption of precision medicine strategies leads to the development
of targeted therapies and fuels market growth. Technological advancements have
facilitated the development of targeted therapies and immunotherapies in breast
cancer treatment. These therapies specifically target cancer cells or boost the
body's immune response against cancer. Advancements in molecular biology,
genomics, and immunology have paved the way for the identification of
therapeutic targets and the development of drugs that precisely target these
specific molecules or immune checkpoints. The availability of targeted
therapies and immunotherapies enhances treatment options, improves patient
outcomes, and contributes to market growth. Technological advancements in drug
delivery systems have improved the efficiency and effectiveness of breast
cancer therapeutics. Novel drug delivery methods, such as nanotechnology-based
systems, liposomal formulations, and targeted drug delivery vehicles, enable
the precise delivery of therapeutics to tumor sites, enhancing their efficacy
while reducing off-target effects. These advancements in drug delivery systems
offer new avenues for treatment and contribute to market growth. Technological
advancements in remote monitoring and telemedicine have gained prominence,
especially in the context of the COVID-19 pandemic. These technologies allow
healthcare providers to remotely monitor patients, provide virtual
consultations, and deliver supportive care services. Remote monitoring and
telemedicine enable timely interventions, reduce the burden on healthcare
systems, and improve patient access to care. The adoption of these technologies
in breast cancer care contributes to market growth and enhances patient
outcomes. In 2022, Abemaciclib (Verzenios) was approved by the National
Institute for Health and Care Excellence (NICE) to treat some people with
breast cancer that has a high-risk of returning.
Download Free Sample Report
Research
and Development
Research
and development (R&D) plays a pivotal role in driving the growth of the
Canada Breast Cancer Therapeutics Market. R&D efforts contribute to a
deeper understanding of the underlying biology of breast cancer. Research
studies aim to unravel the genetic, molecular, and cellular mechanisms involved
in breast cancer development, progression, and response to treatment. These
insights help identify novel therapeutic targets and pathways, leading to the
development of innovative treatment strategies and driving market growth. R&D
activities focus on the discovery and development of new therapeutics for
breast cancer. This includes the identification of potential drug candidates,
preclinical testing, and subsequent clinical trials to evaluate safety and
efficacy. Advances in drug development methodologies, such as high-throughput
screening, computational modeling, and drug repurposing, expedite the discovery
process and contribute to an expanding portfolio of treatment options. R&D
efforts have led to the development of targeted therapies and personalized
medicine approaches in breast cancer treatment. By understanding the genetic
alterations and molecular profiles of breast cancer subtypes, researchers can
design therapies that specifically target these molecular abnormalities.
Targeted therapies exhibit higher efficacy and improved patient outcomes. The
integration of personalized medicine in breast cancer therapeutics drives
market growth and enhances treatment options. R&D activities involve the
conduct of clinical trials to assess the safety and efficacy of new therapeutic
interventions. Clinical trials generate valuable data that support regulatory
approvals and provide evidence for the adoption of novel treatments. The availability
of robust clinical trial data is crucial in establishing the effectiveness of
therapeutics, influencing treatment guidelines, and driving market growth. R&D
in the field of breast cancer therapeutics relies on collaboration among
researchers, pharmaceutical companies, academic institutions, and healthcare
organizations. Collaborative efforts foster knowledge exchange, pooling of
resources, and expertise sharing. These collaborations accelerate the pace of
research, promote innovation, and contribute to the development of new
therapeutics. Public-private partnerships and academic-industry collaborations
play a crucial role in driving market growth.
Growing
Demand for Personalized Medicine
The
growing demand for personalized medicine has a significant influence on the
growth of the Canada Breast Cancer Therapeutics Market. Personalized medicine
aims to provide tailored treatment approaches based on an individual's unique
characteristics, including genetic makeup, tumor biology, and other relevant factors.
In the context of breast cancer, personalized medicine allows healthcare
providers to select treatment options that are more likely to be effective for
specific patient subgroups. This demand for personalized treatment drives the
development and availability of a wide range of targeted therapies,
biomarker-driven therapies, and other personalized medicine interventions. Personalized
medicine in breast cancer therapeutics enhances treatment efficacy. By
understanding the specific genetic alterations and molecular signatures of a
patient's tumor, healthcare providers can select therapies that target these
specific abnormalities. This approach improves treatment response rates,
reduces treatment resistance, and enhances overall treatment outcomes. The demand
for personalized medicine is fueled by the desire for more effective treatments
and improved patient outcomes. Personalized medicine approaches in breast
cancer treatment help minimize adverse effects by tailoring therapies to
individual patients. By considering a patient's genetic profile, biomarker
status, and other factors, healthcare providers can identify treatments that
are more likely to be well-tolerated and have fewer side effects. This
reduction in treatment-related adverse effects leads to improved patient
quality of life and satisfaction. Personalized medicine relies on the
identification of biomarkers associated with specific tumor characteristics or
treatment responses. The growing demand for personalized medicine has spurred research
efforts to identify relevant biomarkers in breast cancer. These biomarkers can
be used in the development of companion diagnostics, which aid in the selection
of appropriate therapies for individual patients. The availability of companion
diagnostics enhances treatment decision-making and contributes to market
growth. The increasing demand for personalized medicine is closely tied to
advancements in genomic sequencing technologies. Next-generation sequencing and
other genomic profiling techniques enable comprehensive analysis of a patient's
tumor, identifying genetic alterations, mutations, and molecular subtypes.
These advancements in genomic sequencing technologies have expanded the scope
of personalized medicine in breast cancer treatment and have driven the
development of targeted therapies and precision medicine approaches.
Growing Collaboration
and Partnerships
Collaboration
and partnerships play a vital role in influencing the growth of the Canada
Breast Cancer Therapeutics Market. Collaboration among researchers,
pharmaceutical companies, academic institutions, and healthcare organizations
fosters knowledge sharing, resource pooling, and expertise exchange. These
collaborative efforts accelerate the pace of R&D activities, leading to advancements
in understanding breast cancer biology, the discovery of new therapeutic
targets, and the development of innovative treatment approaches. Collaborative
R&D initiatives drive innovation, fuel market growth, and contribute to the
expansion of treatment options. Collaborative partnerships enable the sharing
of resources, infrastructure, and expertise among different stakeholders in the
breast cancer therapeutics market. Pharmaceutical companies often collaborate
with academic institutions and research organizations to access specialized
expertise, patient cohorts, and facilities for conducting clinical trials and
preclinical studies. Such collaborations optimize resource utilization, enhance
research capabilities, and expedite the development and commercialization of
new therapies. Collaborative partnerships facilitate technology transfer and
the commercialization of innovative technologies and therapies.
Academic-industry collaborations, for example, allow academic institutions to
transfer their research findings and intellectual property to pharmaceutical
companies for further development and commercialization. These partnerships
expedite the translation of scientific discoveries into clinical applications,
leading to the availability of novel therapies in the market. Partnerships can
be formed to ensure the availability and affordability of therapies to a larger
patient population. Collaborations with healthcare systems, hospitals, and
clinics help ensure the seamless integration of new treatments into clinical
practice and enhance patient access to innovative therapies.
Government Initiatives
and Support
Government
initiatives and support play a crucial role in influencing the growth of the
Canada Breast Cancer Therapeutics Market. Governments provide significant
funding for breast cancer research and development, which fuels innovation in
therapeutics. Funding is often allocated to research institutions, academic
centers, and pharmaceutical companies to support studies focused on understanding
breast cancer biology, discovering new treatment targets, and developing novel
therapies. This financial support drives R&D activities, accelerates the
development of effective treatments, and contributes to the growth of the
market. Government regulatory bodies, such as Health Canada, play a critical
role in ensuring the safety and efficacy of breast cancer therapeutics. These
agencies provide support and guidance to pharmaceutical companies during the
drug development process, facilitating the regulatory approval of new
therapies. Government initiatives, such as expedited review processes and
fast-track designations, help streamline the approval process for promising
breast cancer drugs, allowing quicker access to innovative treatments for patients
and stimulating market growth. Governments invest in healthcare infrastructure
and support initiatives to improve access to breast cancer care. This includes
the establishment of comprehensive cancer centers, the expansion of screening
and diagnostic services, and the enhancement of treatment facilities.
Government support ensures that patients have timely access to high-quality
healthcare services, including the latest advancements in breast cancer
therapeutics. Improved infrastructure and access to care contribute to market
growth by increasing the demand for and utilization of breast cancer
treatments. Governments initiate public awareness and education campaigns to
promote breast cancer screening, early detection, and treatment options. These
campaigns aim to raise awareness about the importance of early diagnosis,
encourage regular screenings, and educate the public about available treatment
modalities. By promoting breast cancer awareness and education, governments
help in early detection, leading to timely interventions and improved treatment
outcomes. Increased awareness and education contribute to the growth of the
market as more individuals seek medical attention and engage in breast cancer
care.
Recent Developments
- Piqray,
a targeted therapy developed by Novartis, gained approval from Health
Canada in June 2019. It is utilized in conjunction with fulvestrant for
the treatment of hormone receptor-positive, HER2-negative advanced or
metastatic breast cancer with a PIK3CA mutation in postmenopausal women
and men. Piqray is a selective PI3K inhibitor that specifically targets a
common genetic alteration in breast cancer.
- Enhertu,
an antibody-drug conjugate developed by AstraZeneca and Daiichi Sankyo,
obtained Health Canada's approval in November 2020. It is indicated for
the treatment of HER2-positive, unresectable, or metastatic breast cancer
in patients who have previously received treatment with trastuzumab and a
taxane. Enhertu combines the HER2-targeting properties of trastuzumab with
a cytotoxic payload, providing a more potent treatment option.
- Trodelvy,
an antibody-drug conjugate developed by Immunomedics, received approval
from Health Canada in December 2020. It is indicated for the treatment of
metastatic triple-negative breast cancer (mTNBC) in patients who have
undergone at least two prior therapies for metastatic disease. Trodelvy
combines an anti-Trop-2 antibody with a cytotoxic payload, allowing
targeted delivery of chemotherapy to cancer cells.
Market Segmentation
Canada
Breast Cancer Therapeutics Market can be segmented by therapy,
end user, region, and competitive landscape. Based on Therapy, Canada Breast
Cancer Therapeutics market can be segmented into Chemotherapy,
Hormone Therapy, Immunotherapy, Targeted Therapy, Others. Based on End User,
the market can be segmented into Hospitals, Specialty Clinics, Ambulatory
Surgical Centers, and Others.
Market
Players
Novartis
Pharmaceuticals Canada Inc, Pfizer Canada Inc, Eli Lilly Canada Inc, Merck
& Co Inc, GlaxoSmithKline Inc/Canada, AstraZeneca Canada Inc, Bristol-Myers
Squibb Canada Inc, Fresenius Kabi Ltd are some of the leading players operating
in the Canada Breast Cancer Therapeutics Market.
|
Attribute
|
Details
|
|
Base Year
|
2022
|
|
Historic
Data
|
2018 – 2021
|
|
Estimated Year
|
2023
|
|
Forecast
Period
|
2024 – 2028
|
|
Quantitative Units
|
Revenue in USD Million, and CAGR for 2018-2022
and 2023-2028
|
|
Report
Coverage
|
Revenue
forecast, company share, competitive landscape, growth factors, and trends
|
|
Segments Covered
|
By Therapy
By End User
By Region
|
|
Regional
scope
|
Ontario
region; Quebec region; Alberta region; British Columbia region; Saskatchewan
and Manitoba region; Rest of Canada
|
|
Key companies profiled
|
Novartis Pharmaceuticals Canada Inc,
Pfizer Canada Inc, Eli Lilly Canada Inc, Merck & Co Inc, GlaxoSmithKline
Inc/Canada, AstraZeneca Canada Inc, Bristol-Myers Squibb Canada Inc,
Fresenius Kabi Ltd
|
|
Customization
scope
|
10% free
report customization with purchase. Addition or alteration to country,
regional & segment scope.
|
|
Pricing and purchase options
|
Avail customized purchase options to
meet your exact research needs. Explore purchase options
|
|
Delivery
Format
|
PDF and Excel
through Email (We can also provide the editable version of the report in
PPT/Word format on special request)
|
Report
Scope:
In
this report, the Canada Breast Cancer Therapeutics market has been segmented
into the following categories, in addition to the industry trends which have
also been detailed below:
- Canada Breast Cancer Therapeutics Market,
By Therapy:
o Chemotherapy
o Hormone Therapy
o Immunotherapy
o Targeted Therapy
o Others
- Canada Breast Cancer Therapeutics Market,
By End User:
o Hospitals
o Specialty Clinics
o Ambulatory Surgical Centers
o Others
- Canada Breast Cancer Therapeutics Market,
By Region:
o
Ontario
o Quebec
o Alberta
o British Columbia
o Saskatchewan and Manitoba
o Rest of Canada
Competitive
Landscape
Company
Profiles: Detailed
analysis of the major companies present in Canada Breast Cancer Therapeutics Market.
Available
Customizations:
With
the given market data, TechSci Research offers customizations according to a
company’s specific needs. The following customization options are available for
the report:
Company
Information
- Detailed analysis and profiling of
additional market players (up to five).
Canada
Breast Cancer Therapeutics Market is an upcoming report to be released soon. If
you wish an early delivery of this report or want to confirm the date of release,
please contact us at [email protected]